Updated on 20 November 2012
The clinical trials will be conducted in parallel and on a global basis including sites in Australia, Belgium, Canada, Finland, France, Germany, Italy, Russia, Spain, Netherlands, Singapore, Malaysia, Taiwan, US and UK. Professor Wischik points out that, "These landmark studies could provide the first definitive data on a Tau-based approach to disease-modifying and preventive treatment of Alzheimer's and FTD, with no Tau-based alternatives generating such data for at least the next five-to-seven years."
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
